Clinical Trials Logo
  1. Home
  2. Throatcarriers of MRSA
  3. NCT01269541
  4. Details
NCT01269541 Clinical Trial

MESS-study MRSA Eradication Study Skåne

Throatcarriers of MRSA Clinical Trial

— MESS  

Official title:
MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01269541
Other study ID # MRSA-2010
Secondary ID 2010-019727-55
Status Completed
Phase N/A
First received January 3, 2011
Last updated August 21, 2017
Start date March 1, 2011
Est. completion date May 1, 2015

Study information
Verified date May 2015
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Recruitment information / eligibility
Status Completed
Enrollment 69
Est. completion date May 1, 2015
Est. primary completion date May 1, 2015
Accepts healthy volunteers No
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria:

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria:

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Mupirocin
Topical in the nose 3 times daily for 5 days
• Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Locations
Country Name City State
Sweden Helsingborg hospital Helsingborg Skåne
Sweden Kristianstad hospital Kristianstad Skåne
Sweden Infectious department SUS Lund Lund Skåne
Sweden SUS Malmö Malmö Skåne
Sweden Örebro university hospital Örebro
Sweden Karolinska university hospital Stockholm

Sponsors (1)
Lead Sponsor Collaborator
Region Skane

Country where clinical trial is conducted

Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Culture for MRSA after 6 months